比较奈他舒地尔与噻吗洛尔在眼压升高患者中安全性和有效性的两项3期临床试验:Rho激酶眼压升高治疗试验1和2(ROCKET-1和ROCKET-2)
两项双盲随机非劣效临床试验纳入1167例开角型青光眼或高眼压症患者,比较奈他舒地尔0.02%每日一次或每日两次与噻吗洛尔0.5%每日两次的眼压降低效果和安全性。奈他舒地尔每日一次在方案人群基线最高眼压<25 mmHg中不劣于噻吗洛尔,结膜充血发生率高于噻吗洛尔(P<.0001)。
要点
- 奈他舒地尔0.02%每日一次降低眼压有临床和统计学意义(P<.001),在基线最高眼压<25 mmHg的方案人群中不劣于噻吗洛尔。
- ROCKET-2中奈他舒地尔每日两次也非劣效于噻吗洛尔。
- 结膜充血是最常见不良事件,奈他舒地尔组发生率50%–59%,噻吗洛尔组8%–11%(P<.0001)。
核心结论
- 在两项大型随机双盲试验中,奈他舒地尔0.02%每日一次对高眼压症和开角型青光眼患者有效且耐受性良好。
- 该分子的新药理作用及房水动力学效应提示其可能成为降眼压药物库的有用补充。
研究设计与样本
- 双盲、随机非劣效临床试验:Rho激酶眼压升高治疗试验1和2(ROCKET-1和ROCKET-2)。
- 纳入开角型青光眼和高眼压症患者,洗脱所有研究前降眼压药物后随机分组。
- ROCKET-1和ROCKET-2共入选1167例患者。
- 分组:奈他舒地尔0.02%每日一次、噻吗洛尔0.5%每日两次,ROCKET-2另设奈他舒地尔0.02%每日两次组。
- 本报告提供两项研究截至3个月的数据。
主要发现
- 奈他舒地尔每日一次较基线眼压降低有临床和统计学意义(P<.001)。
- 在两项研究方案人群基线最高眼压<25 mmHg中,奈他舒地尔每日一次非劣效于噻吗洛尔(ROCKET-2为主要结局指标和人群,ROCKET-1为事后结局指标)。
- ROCKET-2中奈他舒地尔每日两次也非劣效于噻吗洛尔。
- 结膜充血发生率:奈他舒地尔每日一次50%(126/251,ROCKET-2)至53%(108/203,ROCKET-1);奈他舒地尔每日两次59%(149/253,ROCKET-2);噻吗洛尔8%(17/208,ROCKET-1)至11%(27/251,ROCKET-2)。
- 奈他舒地尔与噻吗洛尔结膜充血比较P<.0001。
关键数值与推荐
- 奈他舒地尔0.02%每日一次在方案人群基线最高眼压<25 mmHg中非劣效于噻吗洛尔0.5%每日两次(ROCKET-2主要分析)。
- 奈他舒地尔0.02%每日两次在ROCKET-2中非劣效于噻吗洛尔0.5%每日两次。
- 结膜充血发生率奈他舒地尔每日一次50%(126/251,ROCKET-2)至53%(108/203,ROCKET-1),奈他舒地尔每日两次59%(149/253,ROCKET-2),噻吗洛尔8%(17/208,ROCKET-1)至11%(27/251,ROCKET-2),P<.0001。
临床怎么用
- 原文结论认为奈他舒地尔0.02%每日一次对高眼压症和开角型青光眼患者有效且耐受性良好。
- 原文指出该分子的新药理和房水动力学效应提示其可能成为降眼压药物库的有用补充。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy and ocular and systemic safety of netarsudil 0.02% ophthalmic solution, a rho-kinase inhibitor and norepinephrine transporter inhibitor, in patients with open-angle glaucoma and ocular hypertension. DESIGN: Double-masked, randomized noninferiority clinical trials: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). METHODS: After a washout of all pre-study ocular hypotensive medications, eligible patients were randomized to receive netarsudil 0.02% once daily (q.d.), timolol 0.5% twice a day (b.i.d.), and (ROCKET-2 only) netarsudil 0.02% b.i.d. Data through 3 months from both studies are provided in this report. RESULTS: Enrolled into the 2 studies were 1167 patients. Treatment with netarsudil q.d. produced clinically and statistically significant reductions from baseline intraocular pressure (P < .001), and was noninferior to timolol in the per-protocol population with maximum baseline IOP < 25 mm Hg in both studies (ROCKET-2, primary outcome measure and population, ROCKET-1, post hoc outcome measure). Netarsudil b.i.d. was also noninferior to timolol (ROCKET-2). The most frequent adverse event was conjunctival hyperemia, the incidence of which ranged from 50% (126/251, ROCKET-2) to 53% (108/203, ROCKET-1) for netarsudil q.d., 59% (149/253, ROCKET-2) for netarsudil b.i.d., and 8% (17/208, ROCKET-1) to 11% (27/251, ROCKET-2) for timolol (P < .0001 for netarsudil vs timolol). CONCLUSIONS: In 2 large, randomized, double-masked trials reported here, once-daily dosing of netarsudil 0.02% was found to be effective and well tolerated for the treatment of patients with ocular hypertension and open-angle glaucoma. The novel pharmacology and aqueous humor dynamic effects of this molecule suggest it may be a useful addition to the armamentarium of ocular hypotensive medications.
引用
- Serle JB, Katz LJ, McLaurin E, et al. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2017. PMID: 29199013. doi:10.1016/j.ajo.2017.11.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。